NUCLEUS HYBRID L24 COCHLEAR IMPLANT SYSTEM
Cochlear Americas · Decision date Mar 20, 2014
What did the FDA approve?
FDA records P130016 as an original PMA application. The recorded decision is approval, dated Mar 20, 2014.
FDA approval order statement
APPROVAL FOR THE NUCLEUS HYBRID L24 COCHLEAR IMPLANT SYSTEM. THE NUCLEUS HYBRID L24 COCHLEAR IMPLANT SYSTEM IS INTENDED TO PROVIDE ELECTRIC STIMULATION TO THE MID-TO-HIGH FREQUENCY REGION OF THE COCHLEA AND ACOUSTIC AMPLIFICATION TO THE LOW FREQUENCY REGIONS, FOR PATIENTS WITH RESIDUAL LOW FREQUENCY HEARING SENSITIVITY. THE SYSTEM IS INDICATED FOR UNILATERAL USE IN PATIENTS AGED 18 YEARS AND OLDER WHO HAVE RESIDUALLOW-FREQUENCY HEARING SENSITIVITY AND SEVERE TO PROFOUND HIGH FREQUENCY SENSORINEURAL HEARING LOSS, AND WHO OBTAIN LIMITED BENEFIT FROM APPROPRIATELY FIT BILATERAL HEARING AIDS. TYPICAL PREOPERATIVE HEARING OF CANDIDATES RANGES FROM NORMAL TO MODERATE HEARING LOSS IN THE LOW FREQUENCIES (THRESHOLDS NO POORER THAN 60 DB HL UP TO AND INCLUDING 500 HZ), WITH SEVERE TO PROFOUND MID TO HIGH FREQUENCY HEARING LOSS (THRESHOLD AVERAGE OF 2000, 3000, AND 4000 HZ >=75 DB HL) IN THE EAR TO BE IMPLANTED, AND MODERATELY SEVERE TO PROFOUND MID TO HIGH FREQUENCY HEARING LOSS (THRESHOLD AVERAGE OF 2000, 3000, AND 4000 HZ >=60 DB HL) IN THE CONTRALATERAL EAR. THE CNC WORD RECOGNITION SCORE WILL BE BETWEEN 10% AND 60%, INCLUSIVELY, IN THE EAR TO BE IMPLANTED IN THE PREOPERATIVE AIDED CONDITION AND IN THE CONTRALATERAL EAR WILL BE EQUAL TO OR BETTER THAN THAT OF THE EAR TO BE IMPLANTED BUT NOT MORE THAN 80% CORRECT. PROSPECTIVE CANDIDATES SHOULDGO THROUGH A SUITABLE HEARING AID TRIAL, UNLESS ALREADY APPROPRIATELY FIT WITH HEARING AIDS.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Mar 20, 2014
Regulatory record facts
- Identifier
- P130016
- Regulatory pathway
- Premarket approval application
- Applicant
- Cochlear Americas
- Product code
- PGQ
- Decision code
- APPR
- Decision date
- Mar 20, 2014
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cochlear implant with combined electrical stimulation and acoustic amplification.
- Applicant
- Cochlear Americas
- Product code
- PGQ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P130016 received
Application receipt date recorded by FDA.
P130016 · FDA decision
APPR
P130016/S061 · Related supplement
Cochlear Hybrid Implant System
Timeline entries are records held by MedtechLedger for P130016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Cochlear Hybrid Implant SystemP130016/S061 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cochlear Americas
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 10350 Park Meadows Dr., Lone Tree, CO, 80124
Sources and methodology
- Original FDA record: P130016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records